Ipamorelin

Mechanism of action

Ipamorelin is a 5-amino-acid synthetic peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) designed by the Novo Nordisk group through systematic modification of the GHRP-6 template to maximise growth-hormone-releasing activity while minimising off-target effects on other anterior-pituitary hormones. The four non-standard amino-acid features — α-aminoisobutyric acid (Aib) at position 1, D-2-naphthylalanine (D-2-Nal) at position 3, D-phenylalanine at position 4, and C-terminal amidation — confer protease resistance, optimised receptor binding geometry, and the high selectivity profile that defines its pharmacological niche. The primary molecular target is the growth-hormone secretagogue receptor (GHSR-1a), the cognate ghrelin receptor. Ipamorelin binds GHSR-1a as a full agonist with affinity comparable to native ghrelin and to other GHRP-class compounds, activating Gαq/11-coupled signalling through phospholipase Cβ. The downstream cascade — IP₃-mediated calcium release from intracellular stores, diacylglycerol-mediated PKC activation, and MAPK pathway recruitment — triggers exocytosis of stored growth-hormone vesicles in anterior-pituitary somatotrophs. The pharmacological signature that distinguishes ipamorelin from other GHRP-class peptides is its selectivity profile. In the Raun et al. (Eur J Endocrinol, 1998) characterisation, single intravenous doses of ipamorelin in healthy volunteers produced robust dose-dependent GH release without measurable elevation of plasma cortisol, ACTH, prolactin, aldosterone, or follicle-stimulating hormone — a pharmacological clean-break from the substantial cortisol and prolactin spillover characteristic of GHRP-6 and (to a lesser extent) GHRP-2. The selectivity is thought to reflect a binding mode that engages GHSR-1a in a conformation favouring the GH-releasing signalling bias over the broader anterior-pituitary modulation that ghrelin and less-selective GHRPs produce. GHSR-1a activation alone is mechanistically distinct from GHRH-receptor activation. The GHRH pathway (cAMP/PKA) and the GHRP pathway (Gq/PLC/calcium) converge on GH-vesicle exocytosis through different intracellular signalling but are not mutually redundant — the two pathways have synergistic interactions at the somatotroph level. Co-administration of ipamorelin with a GHRH analogue (sermorelin, CJC-1295 no-DAC) produces GH pulses materially larger than either pathway can elicit alone, with the synergy explained by both receptor-level cross-talk and somatostatin-tone suppression by GHSR-1a-mediated signalling. This is the molecular foundation of the canonical 'CJC-1295 + ipamorelin' research protocol that has become dominant in the GH-secretagogue research community. Ipamorelin's GH-axis effects are downstream-amplified through the canonical GH/IGF-1 cascade: released GH binds the GH receptor on hepatocytes and peripheral tissues, activating JAK2/STAT5 signalling to drive IGF-1 transcription. The integrated metabolic and growth effects are mediated principally through IGF-1 receptor signalling and the downstream PI3K/Akt/mTOR cascade on target tissues. The pulsatile pattern of ipamorelin-driven GH release — discrete pulses lasting approximately 2 hours — preserves the physiological IGF-1 sensitivity that sustained GH delivery (e.g. DAC-variant CJC-1295) would compromise.

Ipamorelin produces dose-dependent growth-hormone release in humans without measurable elevation of cortisol, ACTH, prolactin, aldosterone, or FSH at GH-stimulating doses — establishing the 'selective GHRP' pharmacological category and the principal reason ipamorelin is preferred over GHRP-6 or GHRP-2 for research where GH-axis isolation is required (Raun et al., Eur J Endocrinol, 1998).

— Notable finding

Research history

Ipamorelin was developed by Novo Nordisk in the 1990s as part of a systematic medicinal chemistry programme to identify GHRP-class compounds with improved selectivity for growth-hormone release over the broader anterior-pituitary hormone modulation produced by the original GHRP-6 and GHRP-2 templates. The compound was first characterised in detail by Raun and colleagues in 1998 (Eur J Endocrinol), establishing the dose-dependent GH-releasing activity, the absence of effects on cortisol/ACTH/prolactin/aldosterone, and the favourable acute safety profile in healthy volunteers. The original clinical development target was a once-daily oral or subcutaneous compound for adult growth-hormone deficiency, with the expectation that GHRP-class compounds combined with somatostatin-tone suppression could provide GH replacement with a more physiological pulsatile profile than chronic recombinant somatropin. Phase I and early Phase II development proceeded but the programme did not progress to registration. Specific reasons for Novo Nordisk's discontinuation have not been published in detail, but the broader commercial environment — including the dominance of recombinant somatropin for GH-deficiency indications, the regulatory complexity of pulsatile-dosing pharmacology, and the lack of clearly differentiated clinical efficacy in Phase II — appear to have contributed. The compound entered the research-chemical market in the late 2000s and grew rapidly in the GH-axis research community for its unique selectivity profile. The standard research-chemical-community protocol pairs ipamorelin with the no-DAC variant of CJC-1295 (Mod GRF 1-29) for dual-pathway pulsatile GH release, exploiting both the GHRH-analogue and the GHRP-class agonist mechanisms in a single administration. This 'CJC-1295 + ipamorelin' protocol has become the dominant grey-market research approach to GH-axis modulation, both because of the synergistic GH-release magnitude and because ipamorelin's selectivity avoids the cortisol/prolactin elevations that complicate GHRP-6 and (less severely) GHRP-2 protocols. Ipamorelin holds no marketing authorisation in any jurisdiction. The compound's research-chemical availability, broad publication record (relative to GHRP-2 and hexarelin) and selectivity profile have made it the most-studied GHRP-class peptide outside of GHRP-6.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Acute safety data for ipamorelin in healthy human subjects come primarily from the Raun 1998 characterisation and subsequent Phase I work. Single subcutaneous and intravenous doses across the research dose range produced mild, transient adverse events: brief flushing and warmth following IV bolus, occasional mild transient headache, and infrequent nausea at higher doses. No clinically significant changes in heart rate, blood pressure, or routine haematology/biochemistry were observed at therapeutic dose ranges. No serious adverse events attributable to ipamorelin itself have been documented in the published trials. The defining safety feature is the absence of cortisol/ACTH and prolactin elevation seen with other GHRP-class compounds. GHRP-6 produces 2- to 4-fold cortisol spikes and modest prolactin elevation; GHRP-2 has reduced but non-zero cortisol effects; ipamorelin produces no measurable elevation in either at the GH-stimulating dose range. This selectivity is the principal pharmacological argument for ipamorelin over alternative GHRPs in research where GH-axis isolation is the experimental goal — co-stimulation of cortisol would confound metabolic and immune endpoints in unwanted ways. Chronic-dosing safety data for ipamorelin in humans are limited; Phase II development did not progress, and most chronic-dosing experience derives from research-chemical-community use rather than published clinical trials. Theoretical concerns parallel those for other GH-axis peptides: chronic supraphysiological IGF-1 elevation theoretically carries oncogenic risk through IGF-1R activation; insulin resistance is a documented complication of sustained GH/IGF-1 elevation; the pulsatile-pattern preservation of ipamorelin protocols is expected to mitigate but not eliminate this risk. Ipamorelin's pentapeptide structure (711 Da) is at the lower end of immunogenicity risk; the use of D-amino acids and N-terminal Aib substitution further reduces antibody-response likelihood. Anti-drug antibodies have not been a reported issue in published data. Sterility and endotoxin content of research-chemical-grade preparations remain the dominant practical safety variables, as with all injectable research peptides. No acute hypotension, anaphylaxis, or serious immediate adverse events have been documented at research-protocol doses. The acute safety record is favourable; the chronic-dosing record is necessarily limited by the absence of completed Phase II/III programmes.

UK regulatory status

Ipamorelin is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. Ipamorelin is captured by the World Anti-Doping Agency (WADA) Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth-hormone secretagogue. Athletes subject to anti-doping testing should treat ipamorelin and all GHRP-class peptides as prohibited both in-competition and out-of-competition regardless of claimed research purpose. The compound is captured by IGF-1 elevation monitoring and by GH-isoform-ratio testing in addition to direct peptide identification. MHRA enforcement actions concerning ipamorelin supply specifically have not been published in the public domain. Generic MHRA warnings on unlicensed peptide supply for human use apply. Research-grade ipamorelin for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply or administration to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. For animal research under ASPA (Animals (Scientific Procedures) Act 1986), ipamorelin work in vertebrates requires Personal, Project, and Establishment Licences from the Home Office Drugs and Firearms Licensing Unit, and the work must pass a local Animal Welfare and Ethical Review Body assessment.

Frequently asked questions